Bravo. I wonder if you were to segment film blockbusters according to critics ranking, how many commercially outperformed their intrinsic "value" (As the Screenwriter William Goldman put it, "nobody knows anything"). I also wonder if AI has a shot at changing the economics of the drug industry (maybe it will become cheaper to fail if nothing else).
Alex, I was watching the David Senra interview with Strauss Zelnick (Take Two) and how he learned about the economics of movies early in his career and it struck me as similar to biotech - then I remembered this article about the parallels. You should check out the interview, I think you'll enjoy it!
An excellent analogy and Knightian framing of how revenue distribution can look suspiciously similar across two very different industries. Another layer to consider is the Disruptor phenomenon. As Peter Biskind brilliantly put forth in his 2004 book Down and Dirty Pictures: Miramax, Sundance, and the Rise of Independent Film, it took innovators like Tarantino and Soderbergh paired with a production house like Miramax to shift the landscape.
HealthTech and MedTech start-ups play a similar role. Leveraging wearables, AI-enabled platforms, and direct-to-patient channels, they can challenge existing reimbursement logic, reshape standards of care, and extend patient trust and relationships beyond the patent cliff.
These aren’t just firms or corporations—they are incubators for industry power. The talent that emerges from independent film and start-up biotech often becomes the next generation of gatekeepers (read: investors, directors, KOLs, festival juries, and regulators). The next Club.
Excellent analysis. The question is whether there might be potential disruptors of the landscape looming, analogous to streaming and the music business, smart phones and the phone business, PCs and the computer business. I see 3 candidates that might represent an Andy Grove strategic inflection point, that might overlap/synergize - AI or some form of AI for biomedical data, precision medicine informing therapeutic outcomes for individual patients, and the microbiome as a disease trigger with an increasing shift to disease prevention, resonating with consumers/patients.
Bravo. I wonder if you were to segment film blockbusters according to critics ranking, how many commercially outperformed their intrinsic "value" (As the Screenwriter William Goldman put it, "nobody knows anything"). I also wonder if AI has a shot at changing the economics of the drug industry (maybe it will become cheaper to fail if nothing else).
Alex, I was watching the David Senra interview with Strauss Zelnick (Take Two) and how he learned about the economics of movies early in his career and it struck me as similar to biotech - then I remembered this article about the parallels. You should check out the interview, I think you'll enjoy it!
An excellent analogy and Knightian framing of how revenue distribution can look suspiciously similar across two very different industries. Another layer to consider is the Disruptor phenomenon. As Peter Biskind brilliantly put forth in his 2004 book Down and Dirty Pictures: Miramax, Sundance, and the Rise of Independent Film, it took innovators like Tarantino and Soderbergh paired with a production house like Miramax to shift the landscape.
HealthTech and MedTech start-ups play a similar role. Leveraging wearables, AI-enabled platforms, and direct-to-patient channels, they can challenge existing reimbursement logic, reshape standards of care, and extend patient trust and relationships beyond the patent cliff.
These aren’t just firms or corporations—they are incubators for industry power. The talent that emerges from independent film and start-up biotech often becomes the next generation of gatekeepers (read: investors, directors, KOLs, festival juries, and regulators). The next Club.
Excellent analysis. The question is whether there might be potential disruptors of the landscape looming, analogous to streaming and the music business, smart phones and the phone business, PCs and the computer business. I see 3 candidates that might represent an Andy Grove strategic inflection point, that might overlap/synergize - AI or some form of AI for biomedical data, precision medicine informing therapeutic outcomes for individual patients, and the microbiome as a disease trigger with an increasing shift to disease prevention, resonating with consumers/patients.